What Цитарабин treats: Main Uses and Benefits

Cytarabine is generally applied in clinical settings that involve acute or disruptive episodes, which are conditions characterized by symptoms related to systemic imbalance caused by the disease. It is commonly used as part of the initial symptomatic management plan in Acute Myeloid Leukemia (AML) in both adult and pediatric patients.

This medication is commonly used as a component of the treatment for acute leukemias, including AML, forms of Acute Lymphoblastic Leukemia (ALL), and the blast phase of Chronic Myelogenous Leukemia (CML). This treatment supports the patient by providing a therapeutic benefit that supports the patient during difficult episodes by easing distress, which is important for managing the acute condition.

It is also considered relevant during subsequent consolidation phases of treatment to manage the conditions that may lead to the disease returning, and supports general well-being during symptomatic phases. The treatment is additionally applied to address and prevent meningeal leukemia, where symptoms of increased neurological activity may interfere with daily functioning.

Quick Fact: Support for Acute Symptom Patterns
Cytarabine is applied in scenarios involving acute or unstable symptom patterns, helping to improve day-to-day comfort during periods of heightened disease activity.

Regulatory References

1. NIH DailyMed official label information

Official Eligibility and Restriction Profile

The official regulatory profile for Cytarabine (Цитарабин) strictly defines the population groups permitted or restricted from its use.

Eligibility Scope	Official Regulatory Statement
Populations Contraindicated	Patients with known hypersensitivity to cytarabine or any formulation component must not use the medicine [1.1], [1.2].
	Use is prohibited in the management of non-malignant disease (unless for immunosuppression) [1.1].
Age-Related Rules	Safety in infants (generally under 1 year) is not established [1.2]. High-dose therapy in patients over 60 years requires careful risk-benefit evaluation [1.2].
Condition-Based Limits	Use requires caution and potentially reduced doses in patients with pre-existing impaired hepatic function or poor renal function [1.2], [1.5].
Pregnancy Status	Classified as Pregnancy Category D by the FDA; use during pregnancy is restricted and only permitted on strict indication where maternal benefit outweighs risk [3.2].
Lactation Status	Women are advised not to breastfeed during treatment and for a specified period (e.g., at least 1 week) after the last dose [1.2], [3.3].

The regulatory documentation establishes these restrictions and absolute contraindications based on patient characteristics and pre-existing clinical state. This framing strictly dictates who is officially eligible for use.

Cytarabine Interactions with other medicines and products

Official regulatory documents define specific restrictions and interaction patterns for Cytarabine. Prohibited combinations include the co-administration of live or live-attenuated vaccines due to the serious risk of infection in immunocompromised patients, and concurrent granulocyte transfusions, which have been associated with severe respiratory insufficiency.

Documented Pharmacodynamic and Exposure Interactions

Interaction Type	Interacting Substance	Official Interaction Outcome
Potentiation of Toxicity	Other Cytotoxic Agents	Increased risk of myelosuppression and neurotoxicity.
Antagonism / Reduced Efficacy	Gentamicin, 5-Fluorocytosine (Flucytosine)	Cytarabine may antagonise gentamicin activity; Flucytosine efficacy may be abolished.
Reduced Absorption	Oral Digoxin Tablets	Gastrointestinal absorption may be substantially reduced, resulting in lower plasma concentrations.

Timing and Procedural Constraints

Cytarabine is subject to mandatory physical incompatibility restrictions and must not be mixed with solutions containing agents such as Heparin, Insulin, or Fluorouracil (5-FU). Procedurally, an increased risk of spinal cord toxicity is documented if both the intravenous and intrathecal forms of Cytarabine are administered within a few days of each other. Furthermore, patients with pre-existing hepatic or renal dysfunction have a higher likelihood of CNS toxicity following high-dose treatment.

How Цитарабин Works: Mechanism of Action

Цитарабин functions as a nucleoside analog antagonist of deoxycytidine. Following cellular uptake, the drug is metabolized by Deoxycytidine Kinase (DCK) through phosphorylation, converting it to its active metabolite, ara-CTP. This active form competes with the natural substrate, dCTP, for incorporation into the elongating DNA strand.

The core mechanistic cascade involves ara-CTP being incorporated into DNA by DNA Polymerase, which then causes immediate chain termination. This process arrests DNA replication, primarily affecting cells in the rapid S-phase of the cell cycle, leading to the activation of programmed cell death (apoptosis). The functional consequence of this replication blockade is the inhibition of proliferation in all rapidly dividing cells throughout the body. This mechanism results in predictable systemic physiological consequences, including Myelosuppression (suppression of blood cell production) and damage to fast-renewing tissues like the gastrointestinal epithelium.

Cytarabine is administered exclusively through parenteral routes, which involve injection or infusion directly into the body. There are three primary methods of delivery: intravenous (IV) infusion, subcutaneous (SC) injection, and intrathecal (IT) injection. IV infusion is the standard route for systemic treatment, whereas IT injection is reserved for reaching the Central Nervous System.

The dose is strictly calculated based on the patient's Body Surface Area (m^2), a principle that determines the difference between standard-dose continuous infusions (e.g., 100 mg/m^2 administered over several days) and the highly concentrated high-dose intermittent regimens (e.g., 2 g/m^2 given every 12 hours). The entire treatment is structured into distinct courses or cycles, which mandates a fixed number of administration days followed by drug-free rest periods.

All administration procedures are required to be performed under the direct supervision of a physician experienced in chemotherapy within an appropriate clinical setting. The standard drug must undergo reconstitution and dilution with a specified sterile solution prior to use. Dose modification is required for specific patient populations, including those with pre-existing severe renal or hepatic impairment, to ensure correct administration throughout the full course of therapy.

Research evidence / Overview of studies for Cytarabine

This section provides an overview of the official research, including key clinical trials and meta-analyses, that support the approved uses of Cytarabine. This information describes what studies have been conducted and the types of outcomes they tracked, but it offers no medical advice, instructions, or predictions about individual responses.

---

Evidence for Use in Acute Myeloid Leukemia (AML)

Cytarabine is a subject of research within the protocols for newly diagnosed Acute Myeloid Leukemia (AML). Research primarily consists of Randomized Controlled Trials (RCTs) and meta-analyses that compared Cytarabine-based combination regimens. These studies were used to investigate how different dosing schedules, such as high-dose versus conventional-dose, were associated with differences in outcomes.

The main outcomes that researchers monitored in these trials include Complete Remission (CR) rate and Overall Survival (OS). Findings describe group patterns, showing how outcomes evolved in the observed populations. Research has explored whether a more intense use of Cytarabine in combination is studied for its association with differences in long-term outcomes and relapse patterns for AML in specific patient groups.

---

Evidence in Other Acute Leukemias and the CNS

Cytarabine was also studied for its role in managing other blood cancers, including certain forms of Acute Lymphoblastic Leukemia (ALL) and the blast phase of Chronic Myelogenous Leukemia (CML). For these uses, research often examined the drug as a component within complex, multi-agent protocols.

Research was also conducted on Meningeal Leukemia, which is the clinical situation where leukemia cells are present in the central nervous system. These clinical trials focused on the use of Cytarabine administered directly into the spinal fluid (intrathecally) for both prevention and treatment. The studies monitored cytological clearance, which is the measure of leukemia cells being cleared from the spinal fluid.

---

What is Still Uncertain About Cytarabine Research

Research highlights areas where more data or clarity is needed. The main research limitations include the fact that the results apply only to the populations studied, and the overall evidence quality varies due to the differences across studies due to the wide range of combination regimens and dosing schedules used. Furthermore, comparative evidence is lacking for some of the alternative dosing strategies, and data for certain groups remain insufficient to draw definitive conclusions about long-term survival.

Key Studies & References

1. CYTOSAR (Cytarabine) Powder for solution for injection - U.S. FDA Labeling/Prescribing Information (Reference for indications, CNS use, and high-dose application)
2. Cytarabine - StatPearls - NCBI Bookshelf (Reference for ALL, CML blast phase, and special populations research context)
3. Study Details | NCT00064090 | 3-AP and Cytarabine in Treating Patients With Hematologic Cancer (Example of trials addressing ALL/CML blast phase)

Common questions about Цитарабин (FAQ)

---

Q: Is Цитарабин used for anything other than leukemia?

Official regulatory documents indicate that Cytarabine is approved for treating certain types of lymphomas, specifically meningeal lymphoma, and meningeal leukemia. It is also described for use in these conditions.

---

Q: Is Цитарабин different from other drugs used for AML?

Cytarabine's official classification is an antimetabolite and a nucleoside analog. This means it works by entering cells and interfering with their ability to build DNA, which is essential for cell division. This mechanism of action is one way it is categorized compared to other therapies used for acute myeloid leukemia (AML).

---

Q: Can Цитарабин cause long-term side effects?

Secondary malignancies (cancers) are potential delayed effects associated with many antineoplastic agents. Regulatory documents describe this outcome as an effect that official documents associate with long-term use.

---

Q: Is it normal to feel tired after receiving Цитарабин?

According to official product information, feeling tired or weak is listed as a possible side effect of Cytarabine treatment. Patients may experience these effects during their treatment course.

---

Q: Can Цитарабин affect vision or the eyes?

Yes, official labeling documents various eye disorders as possible side effects. These include reversible haemorrhagic conjunctivitis (eye irritation with bleeding), corneal disorders, eye infections, irritation, pain, and blurred vision.

---

Q: What is 'cytarabine syndrome'?

Official documents describe 'cytarabine syndrome' as a documented reaction that may appear approximately 6 to 12 hours after administration. Symptoms are reported to include fever, malaise (general discomfort), myalgia (muscle pain), bone or chest pain, a skin rash, and eye problems like conjunctivitis.

---

Q: Does Цитарабин affect fertility in men or women?

Regulatory documents indicate that women who may become pregnant must use effective birth control during treatment. The potential for Cytarabine to cause gonadal toxicity (affecting fertility) is also a concern mentioned in official product information for cytotoxic agents.

---

Q: How long does the effect of Цитарабин last in the body?

According to official pharmacokinetics data, Cytarabine is cleared from the body in two phases, known as biphasic elimination. The half-lives, or the time it takes for the concentration to reduce by half, are approximately 10 minutes and then 1 to 3 hours following an intravenous infusion.

---

Q: Is Цитарабин considered a high-risk medication?

Official prescribing information mandates administration only under the constant supervision of physicians experienced in cytotoxic agents in a facility with sufficient supportive resources. This requirement describes the need for careful administration.

---

Q: What is the typical hospital stay when starting Цитарабин therapy?

For induction therapy, treatment must occur in a facility with sufficient laboratory and supportive resources to monitor and maintain a patient compromised by toxicity. The requirement for these resources indicates that the initial phases of treatment are typically provided in an inpatient setting.

---

Q: Is Цитарабин used in high doses or low doses?

Cytarabine is used in a wide range of doses depending on the treatment plan. Regulatory protocols differentiate between conventional doses (e.g., in continuous daily infusions) and high-dose regimens, which use significantly higher concentrations of the drug for intermittent administration.

---

Q: Why is Цитарабин sometimes given intrathecally?

Intrathecal administration involves injecting the drug directly into the cerebrospinal fluid (CSF), which surrounds the brain and spinal cord. This route is used to treat conditions like meningeal leukemia because it allows the drug to reach the Central Nervous System to provide treatment.

---

Q: How does Цитарабин affect blood counts?

The primary toxic effect of Cytarabine is myelosuppression, which is the suppression of bone marrow activity. This directly results in a reduction of blood cell counts, specifically causing leukopenia (low white blood cells), thrombocytopenia (low platelets), and anemia (low red blood cells).

---

Q: Do patients feel nauseous immediately after a Цитарабин infusion?

Official product information on gastrointestinal disorders indicates that nausea and vomiting are generally reported as more frequent when the drug is administered via rapid intravenous injection (IV push) compared to a continuous intravenous infusion.

---

Q: What is the difference between the '7+3' and '5+2' regimens that include Цитарабин?

Official clinical trial data and documentation show these are terms for combination chemotherapy regimens used for acute leukemia. They describe the scheduling where Cytarabine is given for a certain number of days (e.g., 7 or 5 days) alongside another chemotherapy drug for a shorter period (e.g., 3 or 2 days).

---

Q: Are there any official restrictions on activities during Цитарабин treatment?

Regulatory documents state a specific restriction regarding vaccinations. The use of live or live-attenuated vaccines is officially contraindicated (forbidden) during Cytarabine treatment due to the serious risk of infection in patients with a compromised immune system.

---

Q: Can patients drive while undergoing Цитарабин therapy?

The drug's official label documents side effects that include somnolence (drowsiness), dizziness, and effects on the brain and cerebellum. These side effects are noted as potentially impacting motor function, which may affect a person's ability to drive or operate complex machinery.

---

Q: Does smoking affect the safety of Цитарабин?

Authoritative patient information suggests that smoking during Cytarabine treatment may increase some side effects or potentially make the medication less effective. This topic is generally recommended for discussion with a healthcare provider.

Storage and Disposal of Cytarabine

Official regulatory documents define strict requirements for storing and disposing of Cytarabine to maintain its efficacy and safety.

Storage Requirements

Unopened Cytarabine injection vials must be stored at controlled room temperature, generally between 20°C and 25°C. It is mandatory to protect the product from freezing and to keep it in its original container, protected from light. Once reconstituted or diluted, solutions should ideally be used immediately to ensure microbiological quality. If not used right away, storage is limited, and solutions must be visually inspected for particulate matter before use.

Disposal and Safety

Cytarabine must be kept out of the sight and reach of children at all times. Due to its classification as a cytotoxic agent, disposal of unused product, containers, and waste materials must strictly follow local regulations for hazardous medicinal products. Do not dispose of the medication in household trash or down the sink.